Alison Munro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alison Munro has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Avril Taylor
School of Media, Culture and Society, University of the West of Scotland, Paisley, UK
18 shared publications- Sharon J. Hutchinson
Glasgow Caledonian University Glasgow UK
13 shared publications - Norah Palmateer
Sexual Health and Blood Borne Viruses Research Group, Glasgow Caledonian University, Glasgow, Scotland, United Kingdom
9 shared publications David J. Goldberg
School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK; Health Protection Scotland, Meridian Court, Cadogan St, Glasgow, UK
7 shared publications- Andrew McAuley
School of Health and Life Sciences Glasgow Caledonian University Glasgow UK
6 shared publications - Gail Gilchrist
National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London London UK
5 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 29 (64) , 1-118
Optimal provision of opiate substitution therapy and needle and syringe programmes: a multi-method realist evaluation
Background: The barriers and facilitators to engagement with Opiate Substitute Treatment and Needle and Syringe Provision need to be better understood to develop interventions to attract people into services. Objective(s): We conducted a multi-method realist evaluation to generate an in-depth theory of the factors that influence the optimal provision of services in terms of access, engagement, retention and successful exit. Design: Multi-method involving an online survey of United Kingdom drug and alcohol service commissioning leads and a meta-synthesis of qualitative literature (phase 1) to facilitate the development of an initial theory of optimal provision; and, in phase 2, a realist evaluation to test and refine the initial theory, involving in-depth interviews across three United Kingdom sites, with service commissioners, managers, staff and service users. We used routine treatment and staffing data to estimate the additional staff costs of implementing optimal service provision within one context of our refined theory. Results: Findings indicated that optimal provision could be understood with reference to five main contexts [(1) agency and empowerment, (2) self-esteem and respect, (3) knowledge and communication, (4) goals, needs and preferences and (5) resources and demands]. The analysis suggested that optimal provision could be facilitated via specific mechanisms of action, operating at the ‘Systems level’ (policy, legislation and funding) and ‘Service level’ (delivery of services, service pathways, staff roles and responsibilities and organisational culture). Our analysis also identified the potential importance of independent ‘mediating mechanisms’ (e.g. confidence, trust and self-efficacy) which can operate to increase the likelihood of successful service outcomes. A costing analysis estimated the costs associated with a smaller caseload for shared care workers and the implementation of a salary increment scheme at one of the study sites. Limitations: The survey sample size limited generalisability. There was a limited number of United Kingdom studies within the meta-synthesis. The findings of the realist evaluation highlight that provision was not optimised in the observed sites, limiting examples of best practice. However, the conceptual theory of optimal provision can direct future research to facilitate the development and implementation of optimal policy and practice. Conclusions: We have provided a rich understanding of the contexts, mechanisms and actions by which optimal delivery of Opiate Substitute Treatment and Needle and Syringe Provision services may increase the likelihood of successful service provision. A multiagency approach applying various mechanisms within the various contexts of optimal provision may need to be implemented to optimise the provision. Future work: Future research should focus on the development of a multiple-system toolkit or intervention to help drug services to implement optimal provision. More research is also needed to assess, the barriers and facilitators, that vulnerable underserved population and people from minority ethnic groups may face, and the mechanisms to improve provision for these populations. Study registration: This study is registered as PROSPERO 2020 CRD42020209646. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR129798) and is published in full in Health Technology Assessment ; Vol. 29, No. 64. See the NIHR Funding and Awards website for further award information.
- 1 December 2025
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 29 (64) , 1-118
Open AccessOptimal provision of opiate substitution therapy and needle and syringe programmes: a multi-method realist evaluation
Background: The barriers and facilitators to engagement with Opiate Substitute Treatment and Needle and Syringe Provision need to be better understood to develop interventions to attract people into services. Objective(s): We conducted a multi-method realist evaluation to generate an in-depth theory of the factors that influence the optimal provision of services in terms of access, engagement, retention and successful exit. Design: Multi-method involving an online survey of United Kingdom drug and alcohol service commissioning leads and a meta-synthesis of qualitative literature (phase 1) to facilitate the development of an initial theory of optimal provision; and, in phase 2, a realist evaluation to test and refine the initial theory, involving in-depth interviews across three United Kingdom sites, with service commissioners, managers, staff and service users. We used routine treatment and staffing data to estimate the additional staff costs of implementing optimal service provision within one context of our refined theory. Results: Findings indicated that optimal provision could be understood with reference to five main contexts [(1) agency and empowerment, (2) self-esteem and respect, (3) knowledge and communication, (4) goals, needs and preferences and (5) resources and demands]. The analysis suggested that optimal provision could be facilitated via specific mechanisms of action, operating at the ‘Systems level’ (policy, legislation and funding) and ‘Service level’ (delivery of services, service pathways, staff roles and responsibilities and organisational culture). Our analysis also identified the potential importance of independent ‘mediating mechanisms’ (e.g. confidence, trust and self-efficacy) which can operate to increase the likelihood of successful service outcomes. A costing analysis estimated the costs associated with a smaller caseload for shared care workers and the implementation of a salary increment scheme at one of the study sites. Limitations: The survey sample size limited generalisability. There was a limited number of United Kingdom studies within the meta-synthesis. The findings of the realist evaluation highlight that provision was not optimised in the observed sites, limiting examples of best practice. However, the conceptual theory of optimal provision can direct future research to facilitate the development and implementation of optimal policy and practice. Conclusions: We have provided a rich understanding of the contexts, mechanisms and actions by which optimal delivery of Opiate Substitute Treatment and Needle and Syringe Provision services may increase the likelihood of successful service provision. A multiagency approach applying various mechanisms within the various contexts of optimal provision may need to be implemented to optimise the provision. Future work: Future research should focus on the development of a multiple-system toolkit or intervention to help drug services to implement optimal provision. More research is also needed to assess, the barriers and facilitators, that vulnerable underserved population and people from minority ethnic groups may face, and the mechanisms to improve provision for these populations. Study registration: This study is registered as PROSPERO 2020 CRD42020209646. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR129798) and is published in full in Health Technology Assessment ; Vol. 29, No. 64. See the NIHR Funding and Awards website for further award information.
- Open Access
- 1 May 2019
- Published by Elsevier in The Lancet HIV
- Vol. 6 (5) , e315-e324
Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis
- 1 May 2019
- Published by Elsevier in The Lancet HIV
- Vol. 6 (5) , e315-e324
Open AccessRe-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis
- Open Access
- 25 January 2019
- Published by Elsevier in International Journal of Drug Policy
- Vol. 66, 30-37
Emergence of Novel Psychoactive Substance injecting associated with rapid rise in the population prevalence of hepatitis C virus
- 25 January 2019
- Published by Elsevier in International Journal of Drug Policy
- Vol. 66, 30-37
Open AccessEmergence of Novel Psychoactive Substance injecting associated with rapid rise in the population prevalence of hepatitis C virus
- Open Access
- 1 August 2018
- Published by Elsevier in International Journal of Drug Policy
- Vol. 58, 46-54
“Once I’d done it once it was like writing your name”: Lived experience of take-home naloxone administration by people who inject drugs
- 1 August 2018
- Published by Elsevier in International Journal of Drug Policy
- Vol. 58, 46-54
Open Access“Once I’d done it once it was like writing your name”: Lived experience of take-home naloxone administration by people who inject drugs
- Open Access
Modelling the impact of a national scale‐up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland
Background and Aims: To reduce hepatitis C virus (HCV) transmission among people who inject drugs (PWID), Scottish Government‐funded national strategies, launched in 2008, promoted scaling‐up opioid substitution therapy (OST) and needle and syringe provision (NSP), with some increases in HCV treatment. We test whether observed decreases in HCV incidence post‐2008 can be attributed to this intervention scale‐up.Design: A dynamic HCV transmission model among PWID incorporating intervention scale‐up and observed decreases in behavioural risk, calibrated to Scottish HCV prevalence and incidence data for 2008/09.Setting: Scotland, UK.Participants: PWID.Measurements: Model projections from 2008 to 2015 were compared with data to test whether they were consistent with observed decreases in HCV incidence among PWID while incorporating the observed intervention scale‐up, and to determine the impact of scaling‐up interventions on incidence.Findings: Without fitting to epidemiological data post‐2008/09, the model incorporating observed intervention scale‐up agreed with observed decreases in HCV incidence among PWID between 2008 and 2015, suggesting that HCV incidence decreased by 61.3% [95% credibility interval (CrI) = 45.1–75.3%] from 14.2/100 person‐years (py) (9.0–20.7) to 5.5/100 py (2.9–9.2). On average, each model fit lay within 84% (10.1/12) of the confidence bounds for the 12 incidence data points against which the model was compared. We estimate that scale‐up of interventions (OST + NSP + HCV treatment) and decreases in high‐risk behaviour from 2008 to 2015 resulted in a 33.9% (23.8–44.6%) decrease in incidence, with the remainder [27.4% (17.6–37.0%)] explained by historical changes in OST + NSP coverage and risk pre‐2008. Projections suggest that scaling‐up of all interventions post‐2008 averted 1492 (657–2646) infections over 7 years, with 1016 (308–1996), 404 (150–836) and 72 (27–137) due to scale‐up of OST + NSP, decreases in high‐risk behaviour and HCV treatment, respectively.Conclusions: Most of the decline in hepatitis C virus (HCV) incidence in Scotland between 2008 and 2015 appears to be attributable to intervention scale‐up (opioid substitution therapy and needle and syringe provision) due to government strategies on HCV and drugs.
Open AccessModelling the impact of a national scale‐up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland
Background and Aims: To reduce hepatitis C virus (HCV) transmission among people who inject drugs (PWID), Scottish Government‐funded national strategies, launched in 2008, promoted scaling‐up opioid substitution therapy (OST) and needle and syringe provision (NSP), with some increases in HCV treatment. We test whether observed decreases in HCV incidence post‐2008 can be attributed to this intervention scale‐up.Design: A dynamic HCV transmission model among PWID incorporating intervention scale‐up and observed decreases in behavioural risk, calibrated to Scottish HCV prevalence and incidence data for 2008/09.Setting: Scotland, UK.Participants: PWID.Measurements: Model projections from 2008 to 2015 were compared with data to test whether they were consistent with observed decreases in HCV incidence among PWID while incorporating the observed intervention scale‐up, and to determine the impact of scaling‐up interventions on incidence.Findings: Without fitting to epidemiological data post‐2008/09, the model incorporating observed intervention scale‐up agreed with observed decreases in HCV incidence among PWID between 2008 and 2015, suggesting that HCV incidence decreased by 61.3% [95% credibility interval (CrI) = 45.1–75.3%] from 14.2/100 person‐years (py) (9.0–20.7) to 5.5/100 py (2.9–9.2). On average, each model fit lay within 84% (10.1/12) of the confidence bounds for the 12 incidence data points against which the model was compared. We estimate that scale‐up of interventions (OST + NSP + HCV treatment) and decreases in high‐risk behaviour from 2008 to 2015 resulted in a 33.9% (23.8–44.6%) decrease in incidence, with the remainder [27.4% (17.6–37.0%)] explained by historical changes in OST + NSP coverage and risk pre‐2008. Projections suggest that scaling‐up of all interventions post‐2008 averted 1492 (657–2646) infections over 7 years, with 1016 (308–1996), 404 (150–836) and 72 (27–137) due to scale‐up of OST + NSP, decreases in high‐risk behaviour and HCV treatment, respectively.Conclusions: Most of the decline in hepatitis C virus (HCV) incidence in Scotland between 2008 and 2015 appears to be attributable to intervention scale‐up (opioid substitution therapy and needle and syringe provision) due to government strategies on HCV and drugs.
- Open Access
- 1 March 2018
- Published by Elsevier in International Journal of Drug Policy
- Vol. 53, 45-54
Spore forming bacteria infections and people who inject drugs: Implications for harm reduction
- 1 March 2018
- Published by Elsevier in International Journal of Drug Policy
- Vol. 53, 45-54
Open AccessSpore forming bacteria infections and people who inject drugs: Implications for harm reduction
- Open Access
- 1 February 2018
- Published by Elsevier in International Journal of Drug Policy
- Vol. 52, 115-122
Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era
- 1 February 2018
- Published by Elsevier in International Journal of Drug Policy
- Vol. 52, 115-122
Open AccessDeterminants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era
- 16 January 2018
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 21 (3) , 271
Correction to: Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study
The original version of this article unfortunately missed the Acknowledgment.
- 16 January 2018
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 21 (3) , 271
Correction to: Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study
The original version of this article unfortunately missed the Acknowledgment.
- 11 December 2017
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 21 (3) , 259-269
Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study
Women who inject drugs (WWID) are an especially vulnerable group of drug users. This study determined the prevalence of psychiatric comorbidity and intimate partrner violence (IPV), and factors associated with psychiatric comorbidity among WWID recruited from drug treatment services (67%) and harm reduction services in five European regions in Austria, Catalonia, Italy, Poland, and Scotland. Psychiatric comorbidity was assessed among 226 WWID using the Dual Diagnosis Screening Instrument. IPV was assessed using the Composite Abuse Scale and injecting and sexual risk behaviors were assessed using a battery of questionnaires adapted and developed for the study. Eighty-seven percent met criteria for at least one lifetime psychiatric disorder. The most common disorders were depression (76%), panic (54%), and post-traumatic stress (52%). WWID recruited in drug treatment services were almost three times as likely (OR 2.90 95% CI 1.30–6.43; p = 0.007) to meet criteria for a lifetime psychiatric disorder than those recruited from harm reduction services, specifically dysthymia (OR 5.32 95% CI 2.27–12.48; p = 0.000) and post-traumatic stress disorder (OR 1.83 95% CI 1.02–3.27; p = 0.040). WWID who reported sharing needles and syringes were almost three times as likely to meet criteria for lifetime psychiatric comorbidity than those who did not (OR 2.65 95% CI 1.07–6.56). Compared to WWID who had not experienced IPV, victims (70%) were almost two times more likely to meet criteria for post-traumatic stress disorder (OR 1.95 95% CI 1.10–3.48). Psychiatric comorbidity and IPV among WWID are common. Drug treatment and harm reduction services should address psychiatric comorbidity and IPV to improve treatment outcomes.
- 11 December 2017
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 21 (3) , 259-269
Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study
Women who inject drugs (WWID) are an especially vulnerable group of drug users. This study determined the prevalence of psychiatric comorbidity and intimate partrner violence (IPV), and factors associated with psychiatric comorbidity among WWID recruited from drug treatment services (67%) and harm reduction services in five European regions in Austria, Catalonia, Italy, Poland, and Scotland. Psychiatric comorbidity was assessed among 226 WWID using the Dual Diagnosis Screening Instrument. IPV was assessed using the Composite Abuse Scale and injecting and sexual risk behaviors were assessed using a battery of questionnaires adapted and developed for the study. Eighty-seven percent met criteria for at least one lifetime psychiatric disorder. The most common disorders were depression (76%), panic (54%), and post-traumatic stress (52%). WWID recruited in drug treatment services were almost three times as likely (OR 2.90 95% CI 1.30–6.43; p = 0.007) to meet criteria for a lifetime psychiatric disorder than those recruited from harm reduction services, specifically dysthymia (OR 5.32 95% CI 2.27–12.48; p = 0.000) and post-traumatic stress disorder (OR 1.83 95% CI 1.02–3.27; p = 0.040). WWID who reported sharing needles and syringes were almost three times as likely to meet criteria for lifetime psychiatric comorbidity than those who did not (OR 2.65 95% CI 1.07–6.56). Compared to WWID who had not experienced IPV, victims (70%) were almost two times more likely to meet criteria for post-traumatic stress disorder (OR 1.95 95% CI 1.10–3.48). Psychiatric comorbidity and IPV among WWID are common. Drug treatment and harm reduction services should address psychiatric comorbidity and IPV to improve treatment outcomes.
- 1 November 2017
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 21 (72) , 1-312
Preventing blood-borne virus infection in people who inject drugs in the UK: systematic review, stakeholder interviews, psychosocial intervention development and feasibility randomised controlled trial
Background: Opioid substitution therapy and needle exchanges have reduced blood-borne viruses (BBVs) among people who inject drugs (PWID). Some PWID continue to share injecting equipment. Objectives: To develop an evidence-based psychosocial intervention to reduce BBV risk behaviours and increase transmission knowledge among PWID, and conduct a feasibility trial among PWID comparing the intervention with a control. Design: A pragmatic, two-armed randomised controlled, open feasibility trial. Service users were Steering Group members and co-developed the intervention. Peer educators co-delivered the intervention in London. Setting: NHS or third-sector drug treatment or needle exchanges in Glasgow, London, Wrexham and York, recruiting January and February 2016. Participants: Current PWID, aged ≥ 18 years. Interventions: A remote, web-based computer randomisation system allocated participants to a three-session, manualised, psychosocial, gender-specific group intervention delivered by trained facilitators and BBV transmission information booklet plus treatment as usual (TAU) (intervention), or information booklet plus TAU (control). Main outcome measures: Recruitment, retention and follow-up rates measured feasibility. Feedback questionnaires, focus groups with participants who attended at least one intervention session and facilitators assessed the intervention’s acceptability. Results: A systematic review of what works to reduce BBV risk behaviours among PWID; in-depth interviews with PWID; and stakeholder and expert consultation informed the intervention. Sessions covered improving injecting technique and good vein care; planning for risky situations; and understanding BBV transmission. Fifty-six per cent (99/176) of eligible PWID were randomised: 52 to the intervention group and 47 to the control group. Only 24% (8/34) of male and 11% (2/18) of female participants attended all three intervention sessions. Overall, 50% (17/34) of men and 33% (6/18) of women randomised to the intervention group and 47% (14/30) of men and 53% (9/17) of women randomised to the control group were followed up 1 month post intervention. Variations were reported by location. The intervention was acceptable to both participants and facilitators. At 1 month post intervention, no increase in injecting in ‘risky’ sites (e.g. groin, neck) was reported by participants who attended at least one session. PWID who attended at least one session showed a trend towards greater reduction in injecting risk behaviours, a greater increase in withdrawal planning and were more confident about finding a vein. A mean cost of £58.17 per participant was calculated for those attending one session, £148.54 for those attending two sessions and £270.67 for those attending all three sessions, compared with £0.86 in the control group. Treatment costs across the centres vary as a result of the different levels of attendance, as total session costs are divided by attendees to obtain a cost per attendee. The economic analysis suggests that a cost-effectiveness study would be feasible given the response rates and completeness of data. However, we have identified aspects where the service use questionnaire could be abbreviated given the low numbers reported in several care domains. No adverse events were reported. Conclusions: As only 19% of participants attended all three intervention sessions and 47% were followed up 1 month post intervention, a future definitive randomised controlled trial of the intervention is not feasible. Exposure to information on improving injecting techniques did not encourage riskier injecting practices or injecting frequency, and benefits were reported among attendees. The intervention has the potential to positively influence BBV prevention. Harm reduction services should ensure that the intervention content is routinely delivered to PWID to improve vein care and prevent BBVs. Future work: The intervention did not meet the complex needs of some PWID, more tailoring may be needed to reach PWID who are more frequent injectors, who are homeless and female. Limitations: Intervention delivery proved more feasible in London than other locations. Non-attendance at the York trial site substantially influenced the results. Trial registration: Current Controlled Trials ISRCTN66453696 and PROSPERO 014:CRD42014012969. Funding: This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 72. See the NIHR Journals Library website for further project information.
- 1 November 2017
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 21 (72) , 1-312
Preventing blood-borne virus infection in people who inject drugs in the UK: systematic review, stakeholder interviews, psychosocial intervention development and feasibility randomised controlled trial
Background: Opioid substitution therapy and needle exchanges have reduced blood-borne viruses (BBVs) among people who inject drugs (PWID). Some PWID continue to share injecting equipment. Objectives: To develop an evidence-based psychosocial intervention to reduce BBV risk behaviours and increase transmission knowledge among PWID, and conduct a feasibility trial among PWID comparing the intervention with a control. Design: A pragmatic, two-armed randomised controlled, open feasibility trial. Service users were Steering Group members and co-developed the intervention. Peer educators co-delivered the intervention in London. Setting: NHS or third-sector drug treatment or needle exchanges in Glasgow, London, Wrexham and York, recruiting January and February 2016. Participants: Current PWID, aged ≥ 18 years. Interventions: A remote, web-based computer randomisation system allocated participants to a three-session, manualised, psychosocial, gender-specific group intervention delivered by trained facilitators and BBV transmission information booklet plus treatment as usual (TAU) (intervention), or information booklet plus TAU (control). Main outcome measures: Recruitment, retention and follow-up rates measured feasibility. Feedback questionnaires, focus groups with participants who attended at least one intervention session and facilitators assessed the intervention’s acceptability. Results: A systematic review of what works to reduce BBV risk behaviours among PWID; in-depth interviews with PWID; and stakeholder and expert consultation informed the intervention. Sessions covered improving injecting technique and good vein care; planning for risky situations; and understanding BBV transmission. Fifty-six per cent (99/176) of eligible PWID were randomised: 52 to the intervention group and 47 to the control group. Only 24% (8/34) of male and 11% (2/18) of female participants attended all three intervention sessions. Overall, 50% (17/34) of men and 33% (6/18) of women randomised to the intervention group and 47% (14/30) of men and 53% (9/17) of women randomised to the control group were followed up 1 month post intervention. Variations were reported by location. The intervention was acceptable to both participants and facilitators. At 1 month post intervention, no increase in injecting in ‘risky’ sites (e.g. groin, neck) was reported by participants who attended at least one session. PWID who attended at least one session showed a trend towards greater reduction in injecting risk behaviours, a greater increase in withdrawal planning and were more confident about finding a vein. A mean cost of £58.17 per participant was calculated for those attending one session, £148.54 for those attending two sessions and £270.67 for those attending all three sessions, compared with £0.86 in the control group. Treatment costs across the centres vary as a result of the different levels of attendance, as total session costs are divided by attendees to obtain a cost per attendee. The economic analysis suggests that a cost-effectiveness study would be feasible given the response rates and completeness of data. However, we have identified aspects where the service use questionnaire could be abbreviated given the low numbers reported in several care domains. No adverse events were reported. Conclusions: As only 19% of participants attended all three intervention sessions and 47% were followed up 1 month post intervention, a future definitive randomised controlled trial of the intervention is not feasible. Exposure to information on improving injecting techniques did not encourage riskier injecting practices or injecting frequency, and benefits were reported among attendees. The intervention has the potential to positively influence BBV prevention. Harm reduction services should ensure that the intervention content is routinely delivered to PWID to improve vein care and prevent BBVs. Future work: The intervention did not meet the complex needs of some PWID, more tailoring may be needed to reach PWID who are more frequent injectors, who are homeless and female. Limitations: Intervention delivery proved more feasible in London than other locations. Non-attendance at the York trial site substantially influenced the results. Trial registration: Current Controlled Trials ISRCTN66453696 and PROSPERO 014:CRD42014012969. Funding: This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 72. See the NIHR Journals Library website for further project information.